Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

August 5, 2024

Primary Completion Date

December 11, 2024

Study Completion Date

December 11, 2024

Conditions

Depression, Anxiety

Interventions

DRUG

Lysergic Acid Diethylamide (LSD)

one single dose of LSD in the context of psychedelic assisted psychotherapy as a part of a clinical routine in our department

Trial Locations (1)

Geneva University Hospitals, Geneva

All Listed Sponsors

lead

Tatiana Aboulafia Brakha

OTHER

NCT06557239 - Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy | Biotech Hunter | Biotech Hunter